- Home
- AGMH vs BRNS Comparison
AGMH vs BRNS Comparison
Compare AGMH & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMH | BRNS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 24.1M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGMH | BRNS |
|---|---|---|
| Price | $1.44 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 73.7K | 20.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.51 |
| 52 Week High | $18.10 | $2.91 |
Technical Indicators
Market Signals| Indicator | AGMH | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 54.23 |
| Support Level | $1.30 | $0.65 |
| Resistance Level | $1.37 | $0.75 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 83.21 | 48.96 |
Price Performance
Historical ComparisonAbout AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.